Whether you’re an oncologist directing cancer care, or a health creative communicating science, the most consequential decisions are always human. Tech brainpower can inform our choices, but it takes empathy and real-world understanding to figure out what works best. And the question of how health can maximize AI continues to stoke debate.
Tag Archive for: ASCO
Four world-renowned oncologists selected 20 key, non-small cell lung cancer (NSCLC) abstracts presented at the American Society of Clinical Oncology (ASCO) annual conference. Their goal is to use their platform as educators to share unbiased perspectives on the studies’ clinical data, the methodologies, and its potential for improving patient outcomes in lung cancer.
The success of ASCO 2023 demonstrates the organization’s standing as the preeminent group representing all oncologists. The theme, “Partnering with Patients,” also brought the patient-centric focus to the forefront with the message that without them, innovations, breakthrough therapies, and first-in-class drugs would never have occurred.
Observations from ASCO 2023. As oncology becomes an ever more crowded category, marketers need to challenge themselves to do better.
The 2023 American Society of Clinical Oncology (ASCO) meeting had implications for patients, physicians and biopharma companies.
The American Society of Clinical Oncology 2023 annual meeting kicked off Friday in Chicago, and BioSpace’s Greg Slabodkin spoke with leading biopharma analysts about the most-anticipated ASCO abstracts.
Vorasidenib, acquired from Agios in a $1.8 billion deal, slowed the growth of a certain type of low-grade glioma by 61% in a Phase III trial.
The company will present data at the oncology meeting showing the drug’s significant survival benefit in patients with advanced renal cancer and recurrent, persistent and metastatic cervical cancer.
The American Society of Clinical Oncology (ASCO) and the Association of Community Cancer Centers (ACCC) are combining their efforts to increase racial and ethnic diversity in clinical trials.
